Arimoclomol (citrate)

Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP) [1]. Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system[2]. Arimoclomol citrate can be used for the study of Niemann–Pick disease type C.

Product Specifications

CAS Number

[368860-21-3]

Product Name Alternative

BRX-220 (citrate)

UNSPSC

12352005

Hazard Statement

H317, H361, H412

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/arimoclomol-citrate.html

Purity

99.76

Solubility

DMSO : 35 mg/mL (ultrasonic)

Smiles

Cl/C(C1=C[N+]([O-])=CC=C1)=N\OC[C@H](O)CN2CCCCC2.O=C(CC(C(O)=O)(O)CC(O)=O)O

Molecular Formula

C20H28ClN3O10

Molecular Weight

505.90

Precautions

H317, H361, H412

References & Citations

[1]Rakonczay Z Jr, et al. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32 (12) :1283-92.|[2]Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13 (7) :482-96.